MET Inhibitor Fails to Prolong Life in NSCLC Trial | Lung Cancer Dispatch | Scoop.it

A clinical trial of a MET inhibitor has been stopped because the drug doesn't keep people with non-small cell lung cancer (NSCLC) alive longer, researchers reported at the 2013 European Cancer Congress in Amsterdam, Netherlands. The phase III trial included 1,048 people with NSCLC, where half were given the MET inhibitor tivantinib, in combination with erlotinib, which inhibits a protein linked to abnormal cell division. Although tivantinib did not extend life, it did keep tumors from growing for awhile (3.6 mo with this drug vs 1.9 mo without it). Now, the researchers are analyzing the results to see if tivantinib benefitted people with tumors that make too much of the MET protein.